Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077494 | 0.80 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2CA12CA1 | |
| SCHEMBL2078815 | 0.80 | NPC1 (0.54) | POLBNPC1RAB9ACA12CA1 | |
| SCHEMBL8370641 | 0.80 | PNMT (0.49) | — | |
| SCHEMBL8007118 | 0.80 | L3MBTL1 (0.54) | WDR5NPC1RAB9ACA12CA1 | |
| SCHEMBL2079407 | 0.79 | NPC1 (0.52) | POLBNPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL2076587 | 0.79 | NPC1 (0.52) | POLBNPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL2078279 | 0.79 | NPC1 (0.52) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL2075952 | 0.79 | NPC1 (0.52) | POLBNPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL10525127 | 0.79 | CHRM1 (0.52) | WDR5POLBMCL1NPC1RAB9A | |
| SCHEMBL3803914 | 0.79 | CA1 (0.59) | CA12CA1CA2CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163751-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-7713963-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-7179839-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| CN-1259307-C | Acylated indanyl amines and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2006-06-14 | — | — | CN | disclosed |
| CN-1491207-A | Acylated indanyl amines and their use as pharmaceuticals | ������ҽҩ�¹�����˾ | 2004-04-21 | — | — | CN | disclosed |
| EP-1373191-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183712-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | WDR5 4177/4885POLB 2961/4885MCL1 1409/4885 |
| US-20030055093-A1 | Acylated indanyl amines and their use as pharmaceuticals | EDNRA, VEGFA, EDNRB | WDR5 4432/4885POLB 2919/4885MCL1 887/4885 |
| US-20070082897-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | EDNRA, EDNRB, VEGFA | WDR5 4208/4885POLB 2932/4885MCL1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.